BEST1 Vectors for Retinal Dystrophy Treatment

The USPTO published patent application US20260098277A1 for BEST1 vectors and their uses in treating retinal dystrophies. The application covers expression constructs containing BEST1-targeted short hairpin RNAs, BEST1 coding sequences, promoters, and additional regulatory elements designed to improve functional BEST1 expression in subjects with BEST1 mutations and associated retinal dystrophies.

Affected parties—including pharmaceutical companies, biotech firms, and research institutions in the gene therapy or ocular therapeutics space—should monitor this application for potential licensing opportunities or freedom-to-operate considerations. This is a published patent application only; it does not grant rights or create compliance obligations. Parties developing competing therapies or seeking collaboration opportunities may wish to review the claims and track prosecution of this application through the USPTO examination process.